INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years [Yahoo! Finance]
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: Yahoo! Finance
on developing treatments that harness the patient's innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer's Disease (AD) for more than three years under the Australian compassionate use program known as the Special Access Scheme (SAS). Both patients, herein referred to as “Patient 1” and “Patient 2,” was an original study participant in the Phase 1b clinical trial (ClinicalTrials.gov ID NCT03943264 ), in the target dose 1mg/kg cohort, which commenced in November of 2019 and completed in September of 2021. In contrast to clinical trials, patients in the SAS receive exclusive care from their primary care physicians, with the Company's involvement limited to supplying XPro™. Reports from the primary care physicians indicate that XPro™ has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients. Fur
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateGlobeNewswire
- INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9GlobeNewswire
- INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsGlobeNewswire
INMB
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- INMB's page on the SEC website